Thu. May 26th, 2022

Hyderabad (Telangana) [India], December 28: Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug.  Optimus Pharma successfully completed the Phase 3 Clinical Trial on 1218 subjects across 29 geographical study sites all over India. “We want to cover maximum demographic diversity into our trial in order to obtain data across the different geographical regions of the country and conclusive evidence that Molnupiravir is able to bring about viral load reduction over 5 days of treatment duration,” said Chairman and Managing Director of Optimus Pharma, Dr D Srinivasa Reddy. Optimus Pharma has developed the API in the house at its R&D centre in Hyderabad. Optimus Pharma has revealed highly promising results of the drug in its ability to reduce viral load and bring out significant symptomatic improvement in patients’ health.

It is to be noted that in the Clinical Trial, Molnupiravir was administered to the subjects along with Standard of Care (SoC) medication as per the approved protocol by CDSCO. The trial was successful in establishing a clinical significant results of ‘Molnupiravir + SoC’ over ‘SoC’ arm.

  • Rate of hospitalization was less in Molnupiravir+SoC when compared to SoC group.
  • Greater clinical improvement observed in Molnupiravir + SoC arm compared to SOC alone by Day 5 and Day 10.
  • Proportion of subjects with RT-PCR negativity at Day 5 and Day 10 was statistically significant in Molnupiravir + SoC arm.
  • Higher viral load reduction was observed in Molnupiravir+ SoC arm
  • No serious safety concerns observed with Molnupiravir in overall study duration, no mortality was observed in the trial across both the arms

 Molnupiravir is administered as an 800 mg dose by orally consuming four capsules of 200mg twice a day. Upon oral administration, Molnupiravir, being a prodrug, is metabolized into its active form and converted into its triphosphate (TP) form. The TP form of Molnupiravir is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription, thereby significantly reducing viral replication.

Optimus Pharma is ready with a commercial quantity of the drug to cater to the unmet medical need of the nation. It is with heartfelt gratitude that we thank the Subject Expert Committee of the CDSCO and the DCGI for their valuable recommendations and guidance for the Clinical Trial, thereby making this project a huge success, said Dr D. Srinivas Reddy (MD Optimus) in his statement to the press. Optimus Pharma is committed to consistently integrating quality, affordability and reliability into their products and ensuring timely access to life-saving medication to whomsoever is in need.

By dsprime

16 thoughts on “Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR”
  1. Receive and send emails through your temporary messaging system. Use our webmail or your favorite email software with our absolutely free disposable email. temp mail

  2. Hi there just wanted to give you a brief heads up and let you know
    a few of the pictures aren’t loading properly. I’m not sure why but
    I think its a linking issue. I’ve tried it in two different browsers
    and both show the same results.

  3. An outstanding share! I have just forwarded this onto a coworker who had been doing a little homework on this.

    And he actually bought me dinner because I found it for him…
    lol. So allow me to reword this…. Thank YOU for the meal!!
    But yeah, thanks for spending time to discuss this issue here on your web site.

  4. Fantastic goods from you, man. I have take note your stuff prior to and you’re simply too excellent.
    I actually like what you’ve received here, certainly like what you are saying and the best way
    in which you are saying it. You’re making it entertaining and you still take care of to keep it sensible.
    I cant wait to learn far more from you. That is actually a terrific website.

  5. I am not sure where you are getting your info, but great topic.
    I needs to spend some time learning much more or
    understanding more. Thanks for fantastic info I was
    looking for this info for my mission.

  6. Hello there! I could have sworn I’ve visited
    your blog before but after going through some of the
    articles I realized it’s new to me. Nonetheless, I’m definitely
    pleased I came across it and I’ll be book-marking it and checking back regularly!

  7. 802385 528014Will you care and attention essentially write-up most with the following in my webpage in essence your website mention of this blog? 183201

  8. I’ve been surfing on-line more than three hours lately, yet I by no
    means discovered any interesting article like yours. It’s beautiful price sufficient for me.
    In my view, if all webmasters and bloggers made just right content as you did, the internet
    can be much more useful than ever before.

Leave a Reply

Your email address will not be published.